Compare Quest Diagnostics Inc (DGX) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Nu Holdings Ltd — how do they compare? Quest Diagnostics Inc trades at $230.77 (market cap $25.48B), while Nu Holdings Ltd trades at $15.89 (market cap $74.30B). The key difference: Nu Holdings Ltd is far larger — about 2.9× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Nu Holdings Ltd for 53 Days on average.
| DGX | NU | |
|---|---|---|
Market Cap | $25.48B | $74.30B |
Volume | 941,866 | 80,294,805 |
Sector | Health | Financials |
52-Week High | $247.45 | $18.76 |
52-Week Low | $173.49 | $11.60 |
Typical Hold Time | 56 Days | 53 Days |
Enterprise Value | $31.23B | $96.91B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
NU Holdings (NU) trades at $15.92, up 2.18% with bullish technical signals from moving averages. The company demonstrates strong fundamental momentum with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income reaching $2.9B. Recent news highlights acquisition speculation around Monzo and Goldman Sachs' bullish stance, though the stock remains volatile amid mixed earnings performance with two misses and one beat in recent quarters.
The outlook remains positive with 56.5% analyst buy ratings and a $16.53 consensus target, though risks include credit concentration (85% customer concentration in Brazil) and rising delinquencies. The stock trades near resistance at $16 with RSI at 91 suggesting overbought conditions, requiring careful entry timing despite strong growth fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
